Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Jul;14(7):858-868.
doi: 10.1016/j.jalz.2018.01.004. Epub 2018 Feb 17.

Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers

Olivier Hanon  1 , Jean-Sébastien Vidal  2 , Sylvain Lehmann  3 , Stéphanie Bombois  4 , Bernadette Allinquant  5 , Jean-Marc Tréluyer  6 , Patrick Gelé  7 , Christine Delmaire  4 , Fredéric Blanc  8 , Jean-François Mangin  9 , Luc Buée  7 , Jacques Touchon  10 , Jacques Hugon  11 , Bruno Vellas  12 , Evelyne Galbrun  13 , Athanase Benetos  14 , Gilles Berrut  15 , Elèna Paillaud  16 , David Wallon  17 , Giovanni Castelnovo  18 , Lisette Volpe-Gillot  19 , Marc Paccalin  20 , Philippe-Henri Robert  21 , Olivier Godefroy  22 , Thierry Dantoine  23 , Vincent Camus  24 , Joël Belmin  25 , Pierre Vandel  26 , Jean-Luc Novella  27 , Emmanuelle Duron  2 , Anne-Sophie Rigaud  2 , Suzanna Schraen-Maschke  7 , Audrey Gabelle  10 ; BALTAZAR study group
Collaborators, Affiliations
Free article
Multicenter Study

Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers

Olivier Hanon et al. Alzheimers Dement. 2018 Jul.
Free article

Abstract

Introduction: Diagnostic relevance of plasma amyloid β (Aβ) for Alzheimer's disease (AD) process yields conflicting results. The objective of the study was to assess plasma levels of Aβ42 and Aβ40 in amnestic mild cognitive impairment (MCI), nonamnestic MCI, and AD patients and to investigate relationships between peripheral and central biomarkers.

Methods: One thousand forty participants (417 amnestic MCI, 122 nonamnestic MCI, and 501 AD) from the Biomarker of AmyLoïd pepTide and AlZheimer's diseAse Risk multicenter prospective study with cognition, plasma, cerebrospinal fluid (CSF), and magnetic resonance imaging assessments were included.

Results: Plasma Aβ1-42 and Aβ1-40 were lower in AD (36.9 [11.7] and 263 [80] pg/mL) than in amnestic MCI (38.2 [11.9] and 269 [68] pg/mL) than in nonamnestic MCI (39.7 [10.5] and 272 [52] pg/mL), respectively (P = .01 for overall difference between groups for Aβ1-42 and P = .04 for Aβ1-40). Globally, plasma Aβ1-42 correlated with age, Mini-Mental State Examination, and APOE ε4 allele. Plasma Aβ1-42 correlated with all CSF biomarkers in MCI but only with CSF Aβ42 in AD.

Discussion: Plasma Aβ was associated with cognitive status and CSF biomarkers, suggesting the interest of plasma amyloid biomarkers for diagnosis purpose.

Keywords: Alzheimer's disease; Amyloid β peptides; CSF biomarkers; Cohort study; Dementia; Mild cognitive impairment; Plasma biomarkers.

PubMed Disclaimer

Publication types